These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29724518)

  • 1. Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study.
    Miller MD; Sze DY; Padia SA; Lewandowski RJ; Salem R; Mpofu P; Haste PM; Johnson MS
    J Vasc Interv Radiol; 2018 Jun; 29(6):867-873. PubMed ID: 29724518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
    Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
    J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and Toxicities after
    Emmons EC; Bishay S; Du L; Krebs H; Gandhi RT; Collins ZS; O'Hara R; Akhter NM; Wang EA; Grilli C; Brower JS; Peck SR; Petroziello M; Abdel Aal AK; Golzarian J; Kennedy AS; Matsuoka L; Sze DY; Brown DB
    Radiology; 2022 Oct; 305(1):228-236. PubMed ID: 35762890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
    Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
    J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
    Kayaleh R; Krzyston H; Rishi A; Naziri J; Frakes J; Choi J; El-Haddad G; Parikh N; Sweeney J; Kis B
    J Vasc Interv Radiol; 2020 Jul; 31(7):1060-1068. PubMed ID: 32534978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
    Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of results after 112 radioembolizations with
    Casáns-Tormo I; Guijarro-Rosaleny J; Lluch-García P; Rodríguez-Parra H; Roselló-Keränen S; Asensio-Valero L
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(4):255-264. PubMed ID: 37269983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma.
    Gabr A; Abouchaleh N; Ali R; Baker T; Caicedo J; Katariya N; Abecassis M; Riaz A; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2018 Nov; 29(11):1502-1510.e1. PubMed ID: 30268638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review.
    Alexander HC; Nguyen CH; Chu MJJ; Tarr GP; Han CH; Thomas RH; Holden AH; Bartlett ASJR
    J Vasc Interv Radiol; 2022 Dec; 33(12):1559-1569.e2. PubMed ID: 36084842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
    Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
    World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry.
    Robinson TJ; Du L; Matsuoka L; Sze DY; Kennedy AS; Gandhi RT; Kouri BE; Collins ZS; Kokabi N; Grilli CJ; Wang EA; Lee JS; Brown DB
    J Vasc Interv Radiol; 2023 Apr; 34(4):694-701.e3. PubMed ID: 36509236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases-A Single-Center Experience.
    Pieper CC; Meyer C; Wilhelm KE; Block W; Nadal J; Ahmadzadehfar H; Willinek WA; Schild HH
    J Vasc Interv Radiol; 2016 Sep; 27(9):1305-1315. PubMed ID: 27461588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
    El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
    Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.